Bellvitge Biomedical Research Institute (IDIBELL)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Lecturer of the Department of Social Psychology and Quantitative Psychology at the University of Barcelona, researcher at the Bellvitge Biomedical Research Institute (IDIBELL) and CIBERSAM
Coordinator of the Neuro-oncology Unit of the Bellvitge Biomedical Research Institute (IDIBELL) and researcher of the Neuroplasticity and Regeneration Group of the Autonomous University of Barcelona
Head of the Cancer Virotherapy Group at the Bellvitge Biomedical Research Institute (IDIBELL).
Emeritus researcher at the Catalan Institute of Oncology (ICO), senior researcher at the Bellvitge Biomedical Research Institute (IDIBELL) and lecturer in the Faculty of Health Sciences at the Universitat Oberta de Catalunya (UOC)
The sperm of men infected with high-risk genotypes of the human papillomavirus (HPV) suffers more damage from oxidative stress and has a weaker immune response, which can lead to reduced fertility. This is one of the conclusions of a study published in the journal Frontiers in Cellular and Infection Microbiology. The research compared the semen of 20 adults infected with high-risk genotypes, seven infected with low-risk genotypes, and 43 adults without infections.
Both sex and gender are associated with distinct networks in the brains of boys and girls, according to an analysis of brain images of 4,757 children in the US. Understanding these neurobiological patterns is important for identifying how sex and gender influence health and for developing specific diagnostic tools, the research team writes in Science Advances.
A drug in gel form cured 100 percent of mice with a very aggressive brain tumor. The authors hope that this is a first step towards helping human patients with glioblastoma, one of the most dangerous brain tumors in humans. The article is published today in PNAS.
A phase 2 clinical trial has tested a type of immunotherapy based on oncolytic viruses in combination with chemotherapy for the treatment of triple-negative breast tumours. The results are published in the journal Nature Medicine.
In the United States, the human papillomavirus vaccine began to be recommended in 2006 for girls aged 9-26 years. A study published in the journal JAMA Health Forum concludes that the campaign significantly reduced the risk of HPV infection in vaccinated women. In addition, herd immunity reduced the likelihood of infection in unvaccinated women.